Alfuzosin hydrochloride

CAS : 81403-68-1

Ref. 3D-FA17277

Informations sur le produit

• Nom: Alfuzosin hydrochloride
• Synonymes: N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolynyl)methylamino]propyl]tetrahydro-2-furancarboxamideAlfotenSL 77-499-10, 2-Furancarboxamide, 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride, 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, hydrochloride (1:1), 2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, monohydrochloride, Alfoten, Alfuzosin Hcl, Alfuzosin Hydrochloride, Alfuzosina [Spanish], Alfuzosine [French], Alfuzosinehydrochloride, Alfuzosinum [Latin], Furancarboxamide Hydrochloride, Hsdb 7290, KBio3_001866, KBioGR_001616, Mittoval, N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahy, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methyl, N-[3-[(4-Amino-6,7-Dimethoxy-2-Quinazolynyl)Methylamino]Propyl]Tetrahydro-2-Furancarboxamide, N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolynyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride, N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolynyl)methylamino]propyl]tetrahydro-2-furancarboxamide, SL-77,499-10, Mittoval, Urion, Xatral, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]oxol, N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide hydrochloride (1:1), Prestwick0_000322, Prestwick1_000322, SPBio_000429, SPBio_002244, Sl 77-499-10, Sl 77499, Sl-77,499-10, Spectrum2_000505, Spectrum3_001063, Spectrum4_001208, Urion, Uroxantral, Uroxatral, Uroxatral hydrochloride, N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-, Xatral, amino)propyl)tetrahydro-, ane-2-carboxamide, dro-2-furancarboxamide
• CAS: 81403-68-1

Description

Alfuzosin is a drug used to treat symptoms of an enlarged prostate. It belongs to the class of drugs called alpha-adrenergic blockers and is used as a treatment for benign prostatic hyperplasia (BPH). Alfuzosin blocks alpha-adrenergic receptors in the prostate, bladder neck, and urethra. This leads to relaxation of smooth muscles and reduced bladder pressure. The recommended dosage is 0.4 mg once per day, taken orally with or without food. Alfuzosin has relatively few side effects and no major drug interactions. However, it should not be taken by people who have congestive heart failure, liver disease, or certain metabolic disorders.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 425.91 g/mol
• Formule: C₁₉H₂₈ClN₅O₄
• Degré de pureté: Min. 95%